Data Integrity Delays: Another Key Takeaway from Ketek

Senator Grassley wants FDA to withhold NDAs from advisory committees if there are pending questions about the authenticity of any of the clinical data. The agency appears to agree. That could represent another roadblock to NDA reviews.

Cole Werble

Sanofi-Aventis dodged a number of bullets during the prolonged post-marketing review of telithromycin ( Ketek) under the watchful eye of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D